$JSPR
Jasper Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024095173 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.434M
YoY Change 20.49%
% of Gross Profit
Research & Development $14.46M
YoY Change -2.65%
% of Gross Profit
Depreciation & Amortization $541.0K
YoY Change 80.33%
% of Gross Profit
Operating Expenses $19.89M
YoY Change 2.72%
Operating Profit -$19.89M
YoY Change 2.72%
Interest Expense $1.284M
YoY Change -10.21%
% of Operating Profit
Other Income/Expense, Net $1.252M
YoY Change 221.03%
Pretax Income -$18.64M
YoY Change 6.25%
Income Tax
% Of Pretax Income
Net Earnings -$18.64M
YoY Change 6.23%
Net Earnings / Revenue
Basic Earnings Per Share -$1.24
Diluted Earnings Per Share -$1.24
COMMON SHARES
Basic Shares Outstanding 15.00M shares
Diluted Shares Outstanding 15.00M shares

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $92.50M
YoY Change -10.97%
Cash & Equivalents $92.50M
Short-Term Investments
Other Short-Term Assets $625.0K
YoY Change -43.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $94.81M
YoY Change -9.9%
LONG-TERM ASSETS
Property, Plant & Equipment $2.071M
YoY Change -25.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.013M
YoY Change 146.47%
Total Long-Term Assets $4.607M
YoY Change -11.18%
TOTAL ASSETS
Total Short-Term Assets $94.81M
Total Long-Term Assets $4.607M
Total Assets $99.41M
YoY Change -9.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.086M
YoY Change -5.22%
Accrued Expenses $8.524M
YoY Change 3.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.46M
YoY Change 4.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $2.264M
YoY Change -1.44%
Total Long-Term Liabilities $2.264M
YoY Change -1.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.46M
Total Long-Term Liabilities $2.264M
Total Liabilities $15.73M
YoY Change -3.31%
SHAREHOLDERS EQUITY
Retained Earnings -$216.5M
YoY Change 41.53%
Common Stock $2.000K
YoY Change -81.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.68M
YoY Change
Total Liabilities & Shareholders Equity $99.41M
YoY Change -9.96%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$18.64M
YoY Change 6.23%
Depreciation, Depletion And Amortization $541.0K
YoY Change 80.33%
Cash From Operating Activities -$14.05M
YoY Change 17.3%
INVESTING ACTIVITIES
Capital Expenditures $274.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$274.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.000K
YoY Change -70.0%
NET CHANGE
Cash From Operating Activities -14.05M
Cash From Investing Activities -274.0K
Cash From Financing Activities 9.000K
Net Change In Cash -14.32M
YoY Change 19.81%
FREE CASH FLOW
Cash From Operating Activities -$14.05M
Capital Expenditures $274.0K
Free Cash Flow -$14.33M
YoY Change 19.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39138
dei Entity Registrant Name
EntityRegistrantName
JASPER THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2984849
dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Bridge Pkwy
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite #102
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
549-1400
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92502000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86887000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2304000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2051000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
94806000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
88938000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2071000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2727000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1106000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1467000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
417000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
417000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1013000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1343000 usd
CY2024Q3 us-gaap Assets
Assets
99413000 usd
CY2023Q4 us-gaap Assets
Assets
94892000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3086000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4149000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1059000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
972000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8314000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7253000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12459000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12374000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1010000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1814000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2264000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2264000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
15733000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
16452000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
492000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
492000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15001353 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15001353 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11163896 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11163896 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300226000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
248039000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216548000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169600000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
83680000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
78440000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99413000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94892000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14455000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14848000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36049000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37950000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5434000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4514000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14905000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13186000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
19889000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
19362000 usd
us-gaap Operating Expenses
OperatingExpenses
50954000 usd
us-gaap Operating Expenses
OperatingExpenses
51136000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19889000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19362000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-50954000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-51136000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1284000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1433000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4120000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3965000 usd
CY2024Q3 jspr Change In Fair Value Of Earnout Liability
ChangeInFairValueOfEarnoutLiability
-20000 usd
CY2023Q3 jspr Change In Fair Value Of Earnout Liability
ChangeInFairValueOfEarnoutLiability
-334000 usd
jspr Change In Fair Value Of Earnout Liability
ChangeInFairValueOfEarnoutLiability
10000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
575000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-114000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-128000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1252000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1818000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4006000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3252000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18637000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-17544000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46948000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47884000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.6
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.68
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15000516 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15000516 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10971945 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10971945 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14442637 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14442637 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10234980 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10234980 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
100310000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1998000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18637000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
83680000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
110205000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000 usd
CY2023Q3 jspr Stock Issued During Period Value Reversal Of Excess Accrued Issuance Costs
StockIssuedDuringPeriodValueReversalOfExcessAccruedIssuanceCosts
40000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1395000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-17544000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
94133000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
78440000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
299000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3300000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47195000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
45000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4649000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46948000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
83680000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35989000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
388000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6600000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96970000 usd
jspr Proceeds From Issuance Initial Atm Offering
ProceedsFromIssuanceInitialATMOffering
100000 usd
jspr Stock Issued During Period Value Atm Offering
StockIssuedDuringPeriodValueATMOffering
4509000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
725000 usd
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-661000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
36000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
8000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4053000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47884000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
94133000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46948000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47884000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1128000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
825000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
361000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
307000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4649000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4053000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
575000 usd
jspr Change In Fair Value Of Earnout Liability
ChangeInFairValueOfEarnoutLiability
10000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
253000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1467000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-663000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-330000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-348000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1079000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1488000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1061000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3245000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-717000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-637000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-48000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41468000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35588000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
456000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
37000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-456000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47195000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
101479000 usd
jspr Proceeds From Issuance Of Common Stock Pursuant To Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockPursuantToEmployeeStockPurchasePlan
45000 usd
jspr Proceeds From Issuance Of Common Stock Pursuant To Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockPursuantToEmployeeStockPurchasePlan
36000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
661000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
299000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
388000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47539000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101242000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5615000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
65617000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87304000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38667000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92919000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104284000 usd
jspr Unpaid Property And Equipment Included In Accounts Payable
UnpaidPropertyAndEquipmentIncludedInAccountsPayable
16000 usd
jspr Reclassification Of Common Stock Warrant Liability To Equity
ReclassificationOfCommonStockWarrantLiabilityToEquity
725000 usd
jspr Letter Of Credit Issued In Connection With Lease Recognition
LetterOfCreditIssuedInConnectionWithLeaseRecognition
8000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Description of Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Jasper Therapeutics, Inc. and its consolidated subsidiary, Jasper Tx Corp. (collectively, “Jasper” or the “Company”), is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. The Company also has ongoing programs in diseases where targeting diseased hematopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is headquartered in Redwood City, California. The Company is a Delaware corporation and was incorporated in March 2018. In September 2021, the Company completed a merger with Amplitude Healthcare Acquisition Corporation and became a public company. </p>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, valuation of earnout liability and the measurement of stock-based compensation expense. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92502000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86887000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
417000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
417000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92919000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87304000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentrations of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company’s cash and cash equivalents are maintained with financial institutions in the United States of America. Cash balances are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced any losses on its cash, cash equivalents and marketable securities’ balances and periodically evaluates the creditworthiness of its financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company’s future financial results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Products developed by the Company require approval from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.</p>
CY2024Q3 jspr Research And Development Prepaid Expenses
ResearchAndDevelopmentPrepaidExpenses
968000 usd
CY2023Q4 jspr Research And Development Prepaid Expenses
ResearchAndDevelopmentPrepaidExpenses
615000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
212000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
877000 usd
CY2024Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
250000 usd
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
250000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
249000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
14000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
625000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
295000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2304000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2051000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5659000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5187000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3588000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2460000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2071000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2727000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000 usd
CY2024Q3 jspr Research And Development Accrued Expenses Current
ResearchAndDevelopmentAccruedExpensesCurrent
4894000 usd
CY2023Q4 jspr Research And Development Accrued Expenses Current
ResearchAndDevelopmentAccruedExpensesCurrent
5169000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2571000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1767000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
849000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8314000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7253000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2264000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2264000 usd
CY2020Q4 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
2300000 usd
jspr Percentage Of Licensing Fees
PercentageOfLicensingFees
0.001 pure
us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.60 pure
CY2024Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.25 pure
jspr Received Aggregate From Cirm
ReceivedAggregateFromCIRM
2300000 usd
CY2023Q4 us-gaap Cash
Cash
700000 usd
CY2024Q3 jspr Other Receivables Milestone
OtherReceivablesMilestone
50000000 usd
CY2023 jspr Received Aggregate From Cirm
ReceivedAggregateFromCIRM
2300000 usd
jspr Sales Milestone Payments
SalesMilestonePayments
9000000 usd
CY2024Q1 jspr License Maintenance Fee
LicenseMaintenanceFee
35000 usd
CY2023Q1 jspr License Maintenance Fee
LicenseMaintenanceFee
25000 usd
us-gaap Derivative Maturity Dates
DerivativeMaturityDates
2021-09-24
jspr Sponsor Description
SponsorDescription
the Sponsor agreed to place the 105,000 earnout shares into escrow (the “Earnout Shares”), which would have been released as follows: (a) 25,000 Earnout Shares would have been released if, during the period from and after September 24, 2021 until September 24, 2024 (the “Earnout Period”), over any twenty trading days within any thirty day consecutive trading day period, the volume-weighted average price of the Company’s common stock (the “Applicable VWAP”) was greater than or equal to $115.00, (b) 50,000 Earnout Shares would have been released if, during the Earnout Period, the Applicable VWAP was greater than or equal to $150.00 and (c) 30,000 Earnout Shares would have been released if, during the Earnout Period, the Applicable VWAP was greater than or equal to $180.00 (the “triggering events”).
CY2024Q3 us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
100000 usd
CY2023Q3 us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
300000 usd
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
100000 usd
jspr Rentable Square Feet With Lease Commencement
RentableSquareFeetWithLeaseCommencement
13400 sqft
jspr Lessor Amount
LessorAmount
400000 usd
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
60 months
us-gaap Operating Lease Cost
OperatingLeaseCost
504000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
504000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
96000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
2000 usd
us-gaap Lease Cost
LeaseCost
600000 usd
us-gaap Lease Cost
LeaseCost
506000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
859000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
834000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M9D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
293000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1187000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
740000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2220000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
151000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2069000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1059000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1010000 usd
jspr Pay Stanford Net
PayStanfordNet
900000 usd
jspr Pay Stanford Net Term
PayStanfordNetTerm
P3Y
jspr First Milestone Agremments
FirstMilestoneAgremments
300000 usd
jspr Second Milestone Agremment
SecondMilestoneAgremment
300000 usd
jspr Third Milestone Agremment
ThirdMilestoneAgremment
300000 usd
CY2021Q1 jspr Sales Milestone Payments
SalesMilestonePayments
9000000 usd
CY2024Q1 jspr License Maintenance Fee
LicenseMaintenanceFee
35000 usd
CY2023Q1 jspr License Maintenance Fee
LicenseMaintenanceFee
25000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15001353 shares
CY2024Q3 jspr Voting Common Stock Percent
VotingCommonStockPercent
0.099 pure
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4938679 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1867518 shares
CY2022Q4 jspr Aggregate Offering Price
AggregateOfferingPrice
15500000 usd
CY2023Q2 jspr Aggregate Offering Price
AggregateOfferingPrice
75000000 usd
CY2024Q3 jspr Underwritten Offering Remained Available
UnderwrittenOfferingRemainedAvailable
75000000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
900000 shares
CY2023Q1 jspr Option To Purchase Of Shares
OptionToPurchaseOfShares
900000 shares
CY2023Q1 jspr Net Proceed
NetProceed
96900000 usd
CY2024Q1 jspr Underwriting Agreement Shares Of Commonstock
UnderwritingAgreementSharesOfCommonstock
3900000 shares
CY2024Q1 jspr Net Proceeds Value
NetProceedsValue
47200000 usd
CY2024Q3 jspr Available Offering Amount
AvailableOfferingAmount
124500000 usd
jspr Fair Market Value Of Common Stock Percentage
FairMarketValueOfCommonStockPercentage
0.85 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
1 pure
jspr Percentage Of Fair Market Value Of Shares
PercentageOfFairMarketValueOfShares
1.10 pure
jspr Future Grant Shares
FutureGrantShares
1865794 shares
jspr Outstanding Options
OutstandingOptions
898164 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4500000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2700000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
16.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
13.48
jspr Future Stockbased Compensation For Unvested Options
FutureStockbasedCompensationForUnvestedOptions
14800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
100000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
35
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
23.95
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.33 pure
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0487 pure
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
400000
CY2024Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P0Y4M24D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1998000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1395000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4649000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4053000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18637000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-17544000 usd
us-gaap Net Income Loss
NetIncomeLoss
-46948000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-47884000 usd
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15097527 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
11081216 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14544955 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10349384 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
4271 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
9404 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
97011 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
105000 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
102318 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
105000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15000516 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15000516 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10971945 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10971945 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14442637 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14442637 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10234980 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10234980 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.6
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.68
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.68
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2076000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1637185 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2076000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1637185 shares
CY2023Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
100000 usd
CY2024Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
100000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2024Q3 jspr Cancellation Of Earnout Share Value
CancellationOfEarnoutShareValue
usd
jspr Cancellation Of Earnout Share Value
CancellationOfEarnoutShareValue
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
jspr Change In Fair Value Of Earnout Liability
ChangeInFairValueOfEarnoutLiability
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
usd
jspr Unpaid Property And Equipment Included In Accounts Payable
UnpaidPropertyAndEquipmentIncludedInAccountsPayable
usd
jspr Reclassification Of Common Stock Warrant Liability To Equity
ReclassificationOfCommonStockWarrantLiabilityToEquity
usd
jspr Letter Of Credit Issued In Connection With Lease Recognition
LetterOfCreditIssuedInConnectionWithLeaseRecognition
usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
shares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001788028

Files In Submission

Name View Source Status
0001213900-24-095173-index-headers.html Edgar Link pending
0001213900-24-095173-index.html Edgar Link pending
0001213900-24-095173.txt Edgar Link pending
0001213900-24-095173-xbrl.zip Edgar Link pending
ea0220052-10q_jasper.htm Edgar Link pending
ea022005201ex31-1_jasper.htm Edgar Link pending
ea022005201ex31-2_jasper.htm Edgar Link pending
ea022005201ex32-1_jasper.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jspr-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jspr-20240930_def.xml Edgar Link unprocessable
jspr-20240930_lab.xml Edgar Link unprocessable
jspr-20240930_pre.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ea0220052-10q_jasper_htm.xml Edgar Link completed
jspr-20240930_cal.xml Edgar Link unprocessable